Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Yeo-Jin Song, Seoung Wan Nam, Chang Hee Suh, Jung Yoon Choe & Dae Hyun Yoo. (2023) Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview. Expert Opinion on Drug Metabolism & Toxicology 19:11, pages 751-768.
Read now
Read now
James T. Rosenbaum & Marcia Friedman. (2022) Seasoning to Perfection: How to Optimize Anti-TNF Therapy. Ocular Immunology and Inflammation 30:4, pages 767-768.
Read now
Read now
Articles from other publishers (37)
Wenliang Dong, Xiaowen Hu, Caiying Wu, Gengchen Wang, Yi Fang, Luwen Shi & Xiaoyan Nie. (2023) Efficacy, safety, and cost-effectiveness of therapeutic drug monitoring (TDM) for TNF inhibitor therapy in rheumatic disease: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism 63, pages 152302.
Crossref
Crossref
Ari Brekkan, Rocío Lledo-Garcia, Brigitte Lacroix, Siv Jönsson, Mats O. Karlsson & Elodie L. Plan. (2023) Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach. Journal of Pharmacokinetics and Pharmacodynamics.
Crossref
Crossref
Xuefei Li, Yi Wang, Ziqiang Chen, Ming Ruan, Can Yang, Maolin Zhou, Ning Li, Lianping Xing, Hao Xu, Ling Yang, Qi Shi, Yongjun Wang, Jinman Chen & Qianqian Liang. (2023) Hepatorenal pathologies in TNF-transgenic mouse model of rheumatoid arthritis are alleviated by anti-TNF treatment. Arthritis Research & Therapy 25:1.
Crossref
Crossref
Hongtao Guo, Li Li, Bin Liu, Peipei Lu, Zhiwen Cao, Xinyu Ji, Li Li, Guilin Ouyang, Zhixin Nie, Aiping Lyu & Cheng Lu. (2023) Inappropriate treatment response to DMARDs: A pathway to difficult-to-treat rheumatoid arthritis. International Immunopharmacology 122, pages 110655.
Crossref
Crossref
Ana T. Rufino, Marisa Freitas, Carina Proença, José M. P. Ferreira de Oliveira, Eduarda Fernandes & Daniela Ribeiro. (2023) Rheumatoid arthritis molecular targets and their importance to flavonoid‐based therapy. Medicinal Research Reviews.
Crossref
Crossref
Muhammad R A Shipa, Maria Di Cicco, Emese Balogh, Naila A Nitu, M D Mainuddin, Naveen Bhadauria, Dev Mukerjee & Euthalia Roussou. (2023) Drug-survival profiling of second-line biologic therapy in rheumatoid arthritis: Choice of another tumour necrosis factor inhibitor or a biologic of different mode of action?. Modern Rheumatology 33:4, pages 700-707.
Crossref
Crossref
Yiyan Guo, Liping Jin, Liang Dong, Mi Zhang, Yehong Kuang, Xiang Chen, Wu Zhu & Mingzhu Yin. (2023) NHWD-1062 ameliorates inflammation and proliferation by the RIPK1/NF-κB/TLR1 axis in Psoriatic Keratinocytes. Biomedicine & Pharmacotherapy 162, pages 114638.
Crossref
Crossref
Sang Hoon Lee, Jae Geun Song & Hyo-Kyung Han. (2022) Site-selective oral delivery of therapeutic antibodies to the inflamed colon via a folic acid-grafted organic/inorganic hybrid nanocomposite system. Acta Pharmaceutica Sinica B 12:11, pages 4249-4261.
Crossref
Crossref
Yan Xie & Yang Liu. (2022)
Does previous use of tumour necrosis inhibitors change the therapeutic effect of interleukin (
IL
)‐17 or
IL
‐12/23 inhibitors on psoriasis and psoriatic arthritis? Results of a systematic review
. Clinical and Experimental Dermatology 47:9, pages 1627-1635.
Crossref
Crossref
Nadia M T Roodenrijs, Paco M J Welsing, Joël van Roon, Jan L M Schoneveld, Marlies C van der Goes, György Nagy, Michael J Townsend & Jacob M van Laar. (2022) Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search. Rheumatology 61:9, pages 3552-3566.
Crossref
Crossref
Marko Barešić, Ljiljana Smiljanić Tomičević, Branimir Anić & Miroslav Mayer. (2022) Successful IL-17A inhibitor cycling in psoriatic arthritis patient: a case report and a literature review. Rheumatology International 42:2, pages 365-370.
Crossref
Crossref
Daniel J. Wong, Diane D. Park, Simon S. Park, Carolyn A. HallerJiaxuan Chen, Erbin DaiLiying LiuAppi R. MandhapatiPradheep EradiBibek DhakalWalter J. Wever, Melinda HanesLijun Sun, Richard D. Cummings & Elliot L. Chaikof. (2021) A PSGL-1 glycomimetic reduces thrombus burden without affecting hemostasis. Blood 138:13, pages 1182-1193.
Crossref
Crossref
Emilio J. Laserna-Mendieta, Sara Salvador-Martín, Ignacio Marín-Jiménez, Luis A. Menchén, Beatriz López-Cauce, Luis A. López-Fernández & Alfredo J. Lucendo. (2021) Comparison of a new rapid method for determination of serum anti-adalimumab and anti-infliximab antibodies with two established ELISA kits. Journal of Pharmaceutical and Biomedical Analysis 198, pages 114003.
Crossref
Crossref
Abdallah Alzoubi, Hashem Kanaan, Dua'a Alhazaimeh, Salam Gharaibeh, Tareq L. Mukattash & Khalid Kheirallah. (2020) Knowledge, attitude, future expectations and perceived barriers of medical students and physicians regarding pharmacogenomics in Jordan. International Journal of Clinical Practice 75:1.
Crossref
Crossref
Walter Reinisch, Krisztina Gecse, Jonas Halfvarson, Peter M Irving, Jørgen Jahnsen, Laurent Peyrin-Biroulet, Gerhard Rogler, Stefan Schreiber & Silvio Danese. (2021) Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease. Inflammatory Bowel Diseases 27:1, pages 106-122.
Crossref
Crossref
Sinem Nihal Esatoglu, Fatma Nihan Akkoc-Mustafayev, Yesim Ozguler, Fatma Ozbakır, Okan K. Nohut, Dilsen Cevirgen, Vedat Hamuryudan, Ibrahim Hatemi, Aykut Ferhat Celik, Hasan Yazici & Gulen Hatemi. (2020) Immunogenicity of Infliximab Among Patients With Behçet Syndrome: A Controlled Study. Frontiers in Immunology 11.
Crossref
Crossref
Abimael González-Hernández, Bruno A. Marichal-Cancino, Enrique García-Boll & Carlos M. Villalón. (2020) The locus of Action of CGRPergic Monoclonal Antibodies Against Migraine: Peripheral Over Central Mechanisms. CNS & Neurological Disorders - Drug Targets 19:5, pages 344-359.
Crossref
Crossref
V. I. Mazurov, I. Z. Gaydukova, Sh. Erdes, T. V. Dubinina, A. M. Pristrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, E. S. Zhugrova, T. V. Plaksina, P. A. Shesternya, T. V. Kropotina, O. V. Antipova, E. A. Smolyarchuk, O. A. Tciupa, D. I. Abdulganieva, S. A. Lapshina, D. G. Krechikova, I. G. Gordeev, O. B. Nesmeyanova, V. V. Tyrenko, E. P. Ilivanova, A. V. Strelkova & A. V. Eremeeva. (2020) Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA. Rheumatology Science and Practice 58:4, pages 376-386.
Crossref
Crossref
John W. Upham & Lisa M. Jurak. (2020) How do biologicals and other novel therapies effect clinically used biomarkers in severe asthma?. Clinical & Experimental Allergy 50:9, pages 994-1006.
Crossref
Crossref
Jun K Khoo, Hayley Barnes, Seraphina Key, Ian N Glaspole & Andrew J Östör. (2020) Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis. Rheumatology 59:9, pages 2217-2225.
Crossref
Crossref
Dinesh Khanna, Yannick Allanore, Christopher P Denton, Masataka Kuwana, Marco Matucci-Cerinic, Janet E Pope, Tatsuya Atsumi, Radim Bečvář, László Czirják, Eric Hachulla, Tomonori Ishii, Osamu Ishikawa, Sindhu R Johnson, Ellen De Langhe, Chiara Stagnaro, Valeria Riccieri, Elena Schiopu, Richard M Silver, Vanessa Smith, Virginia Steen, Wendy Stevens, Gabriella Szücs, Marie-Elise Truchetet, Melanie Wosnitza, Kaisa Laapas, Janethe de Oliveira Pena, Zhen Yao, Frank Kramer & Oliver Distler. (2020) Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. Annals of the Rheumatic Diseases 79:5, pages 618-625.
Crossref
Crossref
Caterina Bodio, Claudia Grossi, Francesca Pregnolato, Ennio Giulio Favalli, Martina Biggioggero, Antonio Marchesoni, Antonella Murgo, Matteo Filippini, Paola Migliorini, Roberto Caporali, Raffaele Pellerito, Francesco Ciccia, Piercarlo Sarzi-Puttini, Federico Perosa, Giuseppe Paolazzi, Ivana Hollan, Klaus Bendtzen, Pier Luigi Meroni & Maria Orietta Borghi. (2020) Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors. Autoimmunity Reviews 19:5, pages 102509.
Crossref
Crossref
Christopher Banfield, Dan Rudin, Indranil Bhattacharya, Kosalaram Goteti, Gang Li, Mina Hassan‐Zahraee, Lisa S. Brown, Kenneth E. Hung, Sylvester Pawlak & Christopher Lepsy. (2020) First‐in‐human, randomized dose‐escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF‐06480605 in healthy subjects. British Journal of Clinical Pharmacology 86:4, pages 812-824.
Crossref
Crossref
Stephan Blüml. (2020) Biologika und „small molecules“ bei der rheumatoiden ArthritisBiologicals and small molecules for rheumatoid arthritis. Zeitschrift für Rheumatologie 79:3, pages 223-231.
Crossref
Crossref
Barry D. Hock, Stewart M. Smith, Christopher J. McEntyre, Judith L. McKenzie, Christiaan Sies & Paula E. Keating. (2019) Development of a competitive binding homogeneous mobility shift assay for the quantification of adalimumab levels in patient serum. Journal of Immunological Methods 474, pages 112672.
Crossref
Crossref
Mohsin El AmraniSabine M. BosmanAnnelies C. EgasC. Erik Hack, Alwin D. R. HuitemaErik M. van Maarseveen. (2019) Simultaneous Quantification of Free Adalimumab and Infliximab in Human Plasma Using a Target-Based Sample Purification and Liquid Chromatography–Tandem Mass Spectrometry. Therapeutic Drug Monitoring 41:5, pages 640-647.
Crossref
Crossref
Qi Wang, Xinyao Xie, Feng Su, Jiaxue Wang, Shi Chen, Qian Wang, Daoli Jiang, Yitong Wang, Tan Zhang, Chang Liu, Min Han, Tao Tao, Quanrui Wu, Nana Xi, Zhanguo Li, Haifeng Song & Yi Fang. (2019) A randomized controlled dose-escalation study of SSS07, a humanized rabbit anti-human TNF alpha antibody, in healthy Chinese adults. International Immunopharmacology 75, pages 105807.
Crossref
Crossref
Ying Xiong, Yan Ma, Nandani Darshika Kodithuwakku, Weirong Fang, Lifang Liu, Fengwen Li, Yahui Hu & Yunman Li. (2019) Protective effects of Clematichinenoside AR against inflammation and cytotoxicity induced by human tumor necrosis factor-α. International Immunopharmacology 75, pages 105563.
Crossref
Crossref
Damiana Scuteri, Annagrazia Adornetto, Laura Rombolà, Maria Diana Naturale, Luigi Antonio Morrone, Giacinto Bagetta, Paolo Tonin & Maria Tiziana Corasaniti. (2019) New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies. Frontiers in Pharmacology 10.
Crossref
Crossref
Yaron Ilan. (2019) Immune rebalancing by oral immunotherapy: A novel method for getting the immune system back on track. Journal of Leukocyte Biology 105:3, pages 463-472.
Crossref
Crossref
Kosaku Murakami & Tsuneyo Mimori. (2019) Recent Advances in Research Regarding Autoantibodies in Connective Tissue Diseases and Related Disorders. Internal Medicine 58:1, pages 5-14.
Crossref
Crossref
Pier Luigi Meroni & Roberta Gualtierotti. 2019. Mosaic of Autoimmunity. Mosaic of Autoimmunity
619
624
.
Laura Magill, Marsilio Adriani, Véronique Berthou, Keguan Chen, Aude Gleizes, Salima Hacein-Bey-Abina, Agnes Hincelin-Mery, Xavier Mariette, Marc Pallardy, Sebastian Spindeldreher, Natacha Szely, David A. Isenberg, Jessica J. Manson, Elizabeth C. Jury & Claudia Mauri. (2018) Low Percentage of Signal Regulatory Protein α/β+ Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients. Frontiers in Immunology 9.
Crossref
Crossref
Barry D. HockJudith L. McKenzieLiping GoddardStewart M. Smith, Christopher J. McEntyrePaula E. Keating. (2018) Discrimination of Anti-drug Antibodies With Neutralizing Capacity in Infliximab- and Adalimumab-Treated Patients: Comparison of the Homogeneous Mobility Shift Assay and the Affinity Capture and Elution Assay. Therapeutic Drug Monitoring 40:6, pages 705-715.
Crossref
Crossref
Meric Ovacik & Kedan Lin. (2018) Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development. Clinical and Translational Science 11:6, pages 540-552.
Crossref
Crossref
Guillaume Le Baut, Laurent Peyrin‐Biroulet, Guillaume Bouguen, Jean‐Marc Gornet, Carmen Stefanescu, Aurélien Amiot, David Laharie, Romain Altwegg, Mathurin Fumery, Caroline Trang, Lucine Vuitton, Marion Simon, Cyrielle Gilletta de Saint Joseph, Stéphane Nahon, Ludovic Caillo, Emilie Del Tedesco, Laurianne Plastaras, Alexandre Aubourg, Guillaume Pineton de Chambrun, Philippe Seksik & Stéphanie Viennot. (2018)
Anti‐
TNF
therapy for genital fistulas in female patients with Crohn's disease: a nationwide study from the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID)
. Alimentary Pharmacology & Therapeutics 48:8, pages 831-838.
Crossref
Crossref
Rosa Bustos, Carlos Zapata, Efraín Esteban, Julio-César García, Edwin Jáuregui & Diego Jaimes. (2018) Label-Free Quantification of Anti-TNF-α in Patients Treated with Adalimumab Using an Optical Biosensor. Sensors 18:3, pages 691.
Crossref
Crossref